Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, Inc., filed a Form 4 on November 13, 2026, disclosing open-market purchases of 41,000 shares of common stock across two transactions on November 11 and November 12, 2026.

Key Highlights

  • First purchase: Puhlmann acquired 6,000 shares of common stock on November 11, 2026, at a price of $0.83 per share.
  • Second purchase: Puhlmann acquired 35,000 shares on November 12, 2026, at a weighted average price of $0.8447, with individual transaction prices ranging from $0.8408 to $0.8450, inclusive.
  • Resulting ownership: Following the two transactions, Puhlmann directly beneficially owns 178,542 shares of common stock.
  • Transaction codes: Both transactions were coded "P" (open-market purchase) with no derivative securities reported.
  • Reporting person role: Puhlmann is identified as Chief Medical Officer of Perspective Therapeutics, Inc., traded on NASDAQ:CATX.

Puhlmann's Two-Day Share Purchases at Perspective Therapeutics

According to the Form 4 filed with the SEC, Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, Inc. (NASDAQ:CATX), reported two open-market purchases of the company's common stock. On November 11, 2026, he acquired 6,000 shares at $0.83 per share, bringing his directly held total to 143,542 shares at that point.

The following day, November 12, 2026, Puhlmann acquired an additional 35,000 shares at a weighted average price of $0.8447. The filing notes, via footnote, that these shares "were purchased in multiple transactions at prices ranging from $0.8408 to $0.8450, inclusive," and that Puhlmann "undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price." After both transactions, his directly held beneficial ownership stood at 178,542 shares of common stock.

No derivative securities were acquired, disposed of, or reported as beneficially owned in Table II of the filing. The Form 4 was signed on November 13, 2026, by Chris Nenno as Attorney-in-Fact for Puhlmann, and no amendment or Rule 10b5-1 plan designation was indicated on the form.

What Was Disclosed

The filing disclosed two open-market purchases of Perspective Therapeutics common stock by Chief Medical Officer Markus Puhlmann on November 11 and 12, 2026, totaling 41,000 shares, with resulting direct beneficial ownership of 178,542 shares.